NASDAQ:GRTS - Nasdaq - US39868T1051 - Common Stock - Currency: USD
0.0322
-0.01 (-31.78%)
The current stock price of GRTS is 0.0322 USD. In the past month the price decreased by -94.46%. In the past year, price decreased by -98.3%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 231 full-time employees. The company went IPO on 2018-09-28. The firm discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
GRITSTONE BIO INC
5959 Horton Street, Suite 300
Emeryville CALIFORNIA 94608 US
CEO: Andrew Allen
Employees: 231
Company Website: https://gritstonebio.com/
Phone: 15108716100
The current stock price of GRTS is 0.0322 USD. The price decreased by -31.78% in the last trading session.
The exchange symbol of GRITSTONE BIO INC is GRTS and it is listed on the Nasdaq exchange.
GRTS stock is listed on the Nasdaq exchange.
6 analysts have analysed GRTS and the average price target is 0.77 USD. This implies a price increase of 2275.78% is expected in the next year compared to the current price of 0.0322. Check the GRITSTONE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GRITSTONE BIO INC (GRTS) has a market capitalization of 3.80M USD. This makes GRTS a Nano Cap stock.
GRITSTONE BIO INC (GRTS) currently has 231 employees.
The Revenue of GRITSTONE BIO INC (GRTS) is expected to decline by -74.34% in the next year. Check the estimates tab for more information on the GRTS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GRTS does not pay a dividend.
GRITSTONE BIO INC (GRTS) will report earnings on 2024-11-07, after the market close.
GRITSTONE BIO INC (GRTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.09).
ChartMill assigns a fundamental rating of 2 / 10 to GRTS. GRTS may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months GRTS reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS increased by 13.49% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -93.33% | ||
ROE | -599.53% | ||
Debt/Equity | 1.83 |
ChartMill assigns a Buy % Consensus number of 43% to GRTS. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 19.29% and a revenue growth -74.34% for GRTS